JP2023545924A5 - - Google Patents
Info
- Publication number
- JP2023545924A5 JP2023545924A5 JP2023518359A JP2023518359A JP2023545924A5 JP 2023545924 A5 JP2023545924 A5 JP 2023545924A5 JP 2023518359 A JP2023518359 A JP 2023518359A JP 2023518359 A JP2023518359 A JP 2023518359A JP 2023545924 A5 JP2023545924 A5 JP 2023545924A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- subject
- sars
- cov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083625P | 2020-09-25 | 2020-09-25 | |
| US63/083,625 | 2020-09-25 | ||
| PCT/US2021/052040 WO2022067091A1 (en) | 2020-09-25 | 2021-09-24 | Systems and methods for expressing biomolecules in a subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545924A JP2023545924A (ja) | 2023-11-01 |
| JP2023545924A5 true JP2023545924A5 (enExample) | 2024-10-04 |
Family
ID=80845864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518359A Pending JP2023545924A (ja) | 2020-09-25 | 2021-09-24 | 対象における生体分子を発現するためのシステム及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240156960A1 (enExample) |
| EP (1) | EP4216935A1 (enExample) |
| JP (1) | JP2023545924A (enExample) |
| KR (1) | KR20230086663A (enExample) |
| CN (1) | CN116615233A (enExample) |
| AU (1) | AU2021350020A1 (enExample) |
| CA (1) | CA3192229A1 (enExample) |
| IL (1) | IL300776A (enExample) |
| WO (1) | WO2022067091A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116392609A (zh) | 2017-03-23 | 2023-07-07 | Dnarx公司 | 用于体内核酸表达的系统和方法 |
| WO2021226405A1 (en) * | 2020-05-06 | 2021-11-11 | International Aids Vaccine Initiative Inc. | Covid-19 antibodies and uses thereof |
| WO2025049908A1 (en) * | 2023-09-01 | 2025-03-06 | Normunity, Inc. | Anti-pla2g10 antibodies and methods of use |
| WO2025054427A1 (en) * | 2023-09-07 | 2025-03-13 | Quantum-Si Incorporated | Quenchbody development |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201811076T4 (tr) * | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| CN116392609A (zh) * | 2017-03-23 | 2023-07-07 | Dnarx公司 | 用于体内核酸表达的系统和方法 |
| CN111647077B (zh) * | 2020-06-02 | 2021-02-09 | 深圳市因诺赛生物科技有限公司 | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 |
-
2021
- 2021-09-24 CA CA3192229A patent/CA3192229A1/en active Pending
- 2021-09-24 WO PCT/US2021/052040 patent/WO2022067091A1/en not_active Ceased
- 2021-09-24 JP JP2023518359A patent/JP2023545924A/ja active Pending
- 2021-09-24 CN CN202180078551.8A patent/CN116615233A/zh active Pending
- 2021-09-24 KR KR1020237009206A patent/KR20230086663A/ko active Pending
- 2021-09-24 IL IL300776A patent/IL300776A/en unknown
- 2021-09-24 EP EP21873552.0A patent/EP4216935A1/en not_active Withdrawn
- 2021-09-24 AU AU2021350020A patent/AU2021350020A1/en not_active Abandoned
-
2023
- 2023-02-09 US US18/166,962 patent/US20240156960A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2525179T3 (es) | Derivado de neuromedina U | |
| CN105294859A (zh) | 脂蛋白复合物及其制备和用途 | |
| US20030185795A1 (en) | Oral delivery of chemically modified proteins | |
| JPWO2009044918A1 (ja) | ニューロメジンｕ誘導体 | |
| US20210130487A1 (en) | Cd20-targeted antibody coupling pharmaceutical preparation | |
| JP2023545924A (ja) | 対象における生体分子を発現するためのシステム及び方法 | |
| Bestman-Smith et al. | Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1 | |
| JP2007500741A (ja) | 一時的処置のための短い半減期を有するｃ１インヒビター | |
| WO2023122535A2 (en) | Nucleic acid expression using subcutaneous administration | |
| KR20230079132A (ko) | 안질환을 치료하는 데 사용하기 위한 지질 결합 단백질-기반 복합체를 포함하는 조성물 | |
| WO1998022092A1 (en) | Transport of liposomes across the blood-brain barrier | |
| JP2023533797A (ja) | 脂質複合体を含む経口医薬組成物 | |
| US20250235532A1 (en) | Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof | |
| JP2001512463A (ja) | Ｂ型肝炎ウィルス（ｈｂｖ）感染症を処置するための薬理組成物 | |
| EP0839046B1 (en) | Tnf receptor and steroid hormone dhea in a combined therapy | |
| AU2024234229A1 (en) | Annexin a1 administration regime | |
| US11229683B2 (en) | Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure | |
| JP2025534459A (ja) | 細胞透過性ペプチド及びその使用 | |
| JP2000507207A (ja) | 複合注射剤 | |
| KR20180102091A (ko) | 당뇨병의 치료를 위한 약제학적 제제 | |
| EP1616182A2 (en) | Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 | |
| US10183067B1 (en) | TAA/CD4OL composition/vaccine for malaria | |
| ES2285755T3 (es) | Material biologico para el tratamiento de un mamifero por transferencia de genes de anticuerpos y composicion farmaceutica que lo contiene. | |
| JP2001518917A (ja) | 免疫修飾処置によるトランスジェニックタンパク質の発現の延長 | |
| KR102964997B1 (ko) | 호중구 감소증을 예방하거나 또는 호중구 감소증의 지속기간을 감소시키기 위한 지속성 g-csf |